447 related articles for article (PubMed ID: 23114159)
21. Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis.
Manske MK; Zuckerman NS; Timm MM; Maiden S; Edelman H; Shahaf G; Barak M; Dispenzieri A; Gertz MA; Mehr R; Abraham RS
Clin Immunol; 2006 Jul; 120(1):106-20. PubMed ID: 16515886
[TBL] [Abstract][Full Text] [Related]
22. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
23. Clinical and morphological diagnosis of cardiac AL amyloidosis: a review of findings and difficulties as illustrated in one case.
Prochorec-Sobieszek M; Szufladowicz E; Szaroszyk W; Wagner T; Loukas M
Med Sci Monit; 2005 Aug; 11(8):CS45-8. PubMed ID: 16049384
[TBL] [Abstract][Full Text] [Related]
24. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
[TBL] [Abstract][Full Text] [Related]
25. [The clinical significance of serum free light chain in primary systemic amyloidosis].
Zhai YP; Song P; Li F; Liu HN; Yu YP; Zhou XG; Shi P; An ZM; Zhou X; Zhang CN
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):404-7. PubMed ID: 21624224
[TBL] [Abstract][Full Text] [Related]
26. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
27. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
Cohen AD; Comenzo RL
Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
[TBL] [Abstract][Full Text] [Related]
28. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
29. Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom.
Kon T; Nakagawa N; Yoshikawa F; Haba K; Kitagawa N; Izumi M; Kumazaki S; Ishida S; Aikawa R
Clin J Gastroenterol; 2016 Aug; 9(4):243-51. PubMed ID: 27318996
[TBL] [Abstract][Full Text] [Related]
30. Primary AL (kappa-light chain) amyloidosis manifesting as peripheral neuropathy in a young male without increase in serum and urine immunoglobulin load: a diagnostic challenge.
Sarkar C; Chand Sharma M; Nayak A; Mercy Ralte A; Gupta V; Singh S; Behari M
Clin Neuropathol; 2005; 24(3):118-25. PubMed ID: 15943163
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
32. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases.
Swan N; Skinner M; O'Hara CJ
Am J Clin Pathol; 2003 Oct; 120(4):610-6. PubMed ID: 14560572
[TBL] [Abstract][Full Text] [Related]
35. Immunoglobulin-related (AL) amyloidosis.
Husby G
Clin Exp Rheumatol; 1983; 1(4):353-8. PubMed ID: 6442636
[TBL] [Abstract][Full Text] [Related]
36. Therapies for cardiac light chain amyloidosis: An update.
Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
[TBL] [Abstract][Full Text] [Related]
37. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
39. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
